MUTANTES CHANNELRHODOPSIN-2

European patent · EP2614079 · In force

Register entry

Publication number
EP2614079
Application number
EP11760432
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Sep 8, 2011
Published
Jul 17, 2013
Granted
Jul 15, 2015
Protection ends at the latest
Sep 7, 2031
Next annual fee due
Sep 30, 2027
IPC classes
C07K 14/705 (2006.01)
Priority
US 380793 P 08.09.2010
EP 10175832 08.09.2010
PCT application
PCT/EP2011/065510 08.09.2011
PCT publication
WO2012/032103 15.03.2012
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Oct 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.09.2026 → 30.09.2027

    Published in Swissreg on 01.10.2026

  2. Oct 1, 2025

    Next annual fee due on

    Next annual fee due on
    30.09.2025 → 30.09.2026

    Published in Swissreg on 01.10.2025

  3. Oct 3, 2024

    Change

    Published in Swissreg on 03.10.2024

  4. Oct 1, 2023

    Change

    Published in Swissreg on 01.10.2023

  5. Oct 1, 2022

    Change

    Published in Swissreg on 01.10.2022

  6. Jul 15, 2015

    Granted

    Published in Swissreg on 15.07.2015

Parties

Holder

Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

Hofgartenstrasse 8, 80539 München, DE

Inventor

BAMBERG, Ernst

65779 Kelkheim, DE

BAMANN, Christian

60594 Frankfurt, DE

KLEINLOGEL, Sonja

61449 Steinbach/Ts., DE

WOOD, Phillip

66839 Schmelz, DE

DEMPSKI, Robert E.

Worcester, MA 01609, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.